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Background: Subarachnoid hemorrhage (SAH) is a neurological disease with a high mortality rate. Several serious
complications frequently arise after successful surgery for this condition. Cerebral vasospasm, one such complication,
occurs in 50 to 70% of SAH patients. These patients suffer neurological symptoms known as delayed ischemic
neurological deficit (DIND); however, the effect of treatment of vasospasm is limited. The major pathogenesis of
cerebral vasospasm is the reduction of nitric oxide (NO) and activation of vasoconstrictors. Acupuncture is known
to increase the production and activity of vascular endothelial cell-derived NO and improve endothelium-dependent
vasodilatation. A preliminary retrospective case study to investigate the ability of acupuncture to prevent the
occurrence of cerebral vasospasm has been conducted. However, no randomized, controlled clinical trials have
been carried out to evaluate the efficacy of acupuncture for cerebral vasospasm.
Methods/Design: This trial will be a single-center, randomized, placebo-controlled, parallel group, patient-assessor-blinded
clinical trial. A total of 80 patients with SAH will be randomized into two groups: a study group given acupuncture,
electroacupuncture, and intradermal acupuncture, and a control group given mock transcutaneous electrical nerve
stimulation and sham intradermal acupuncture. Intervention will start within 96 h after SAH, and a total of 12 sessions
will be performed during a 2-week period. The primary outcome measure will be the occurrence of DIND, and the
secondary outcomes will be vasospasm as measured by cerebral angiography, transcranial Doppler, clinical symptoms,
vasospasm-related infarcts, NO and endothelin-1 plasma levels, mortality, and modified Rankin Scale scores.
Discussion: This trial will examine the efficacy and safety of acupuncture for cerebral vasospasm after SAH. The placebo
effect will be excluded and the mechanism of action of the treatments will be evaluated through blood testing.
Trial registration: ClinicalTrials.gov NCT02275949, Registration date: 26 October 2014.
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Subarachnoid hemorrhage (SAH) can occur spontan-
eously or as a result of trauma [1]. The most common
cause of spontaneous SAH is aneurysm rupture (about
80% of cases), while vascular malformations, tumors,
venous angioma, or infectious aneurysms may also
cause bleeding [2,3]. The incidence rate is about 1 per
10,000 people per year, and SAH accounts for about 5%
of stroke patients [3,4]. The rate of SAH is low when
compared to cerebral hemorrhage or cerebral infarc-
tion; however, this condition is a large burden to both
individual patients and society because of high mortal-
ity rates and treatment costs in neurological intensive
care units [5-7].
Treatment of SAH involves early ligation of the
aneurysm or insertion of a coil; however, complications
such as cerebral vasospasm, rebleeding, or hydroceph-
alus frequently occur after successful surgery [2-4,7,8].
Such complications increase the mortality rate of SAH
or lead to patient sequelae [4]. In particular, cerebral
vasospasm is the most serious complication of SAH
[9]. It is reported that 23% of the deaths or disabilities
that occur as a result of SAH are due to vasospasm
[10]. Cerebral vasospasm begins 3 to 4 days after the
onset of SAH and reaches a maximum between 7 and
10 days [7,11,12]. Vasospasm occurs in 50 to 70% of
SAH patients, and about 50% of these patients suffer
neurological symptoms such as deterioration of con-
sciousness and language disorders [3,11,13]. Such
symptoms are known as delayed ischemic neurological
deficit (DIND). Cerebral infarction occurs in half of
DIND patients and a permanent neurological deficit
remains in about 35%. In addition, 30% of patients die
of DIND [4,7].
Spontaneous vasoconstriction and vasodilatation are
adjusted by the physiological regulation of vascular
endothelial cells [14]. If a cerebral aneurysm ruptures
and cerebral blood flow enters the subarachnoid space,
hemoglobin in the blood increases the production of
reactive oxygen species (ROS) [15]. This triggers secre-
tion of the vasoconstrictor substances endothelin-1,
prostaglandin H2, and thromboxane A2 from vascular
endothelial cells and decreases levels of the vasodilatory
substance nitric oxide (NO) [6,9,10,15,16]. It is known
that cerebral vasospasm occurs via this mechanism. In
particular, NO and hemoglobin combine very easily;
thus, the presence of hemoglobin results in the loss of
vasodilatory function [16]. To prevent vasospasm on
the basis of its pathogenesis, various methods such as
calcium channel blockers, magnesium sulfate, statin
agents, endothelin antagonists, and nicardipine pro-
longed release implants have been used [2,3,7]. How-
ever, their effects are limited and various studies of new
drugs and treatments are now under way [4,9,10].Acupuncture is an effective and safe treatment method
that has been used for the treatment of acute stroke
including SAH for centuries [17]. In recent years, a
number of studies have been published that show that
acupuncture increases the production and activity of
vascular endothelial cell-derived NO and can improve
the function of damaged vascular endothelial cells
[18,19]. Acupuncture point ST36 (Zusanli) is known to
lower blood pressure and sympathetic nervous tension
[18,19]. In particular, it was reported that electroacu-
puncture stimulation at ST36 lowers blood pressure by
increasing the activity of endothelial NO [19]. NO
released from endothelial cells plays a key role in main-
taining the tension of the vascular wall [20]. Since
reduction of NO is the major pathogenesis of cerebral
vasospasm after SAH, it can be assumed that acupunc-
ture at ST36 will stimulate the production of NO and
normalize endothelial function in patients with SAH.
Another acupoint, PC6 (Neiguan), is known to reduce
the ischemic heart damage caused by increased myo-
cardial oxygen demand as a result of sympathetic
nervous excitement; it also lowers blood pressure and
reduces nausea and vomiting [21]. In a study using a
finger photoplethysmogram, acupuncture at PC6 was
reported to be effective in reducing arterial stiffness in
hypertensive patients [22]. Although this study was per-
formed to investigate the acute reaction to acupuncture, it
can be assumed that acupuncture at PC6 normalized
endothelial cell function and so reduced arterial stiffness.
Based on previous reports, a clinical study was con-
ducted in hypertensive patients with damaged arterial
endothelial cell function, which confirmed that acupunc-
ture at ST36-PC6 improved endothelium-dependent
vasodilatation [23]. After this, we carried out a prelimin-
ary retrospective case study in patients with SAH. The
results indicated the possibility of acupuncture treatment
in preventing the occurrence of cerebral vasospasm after
SAH [24]. To confirm the effectiveness and clinical
application of acupuncture for cerebral vasospasm,
rigorous clinical trials such as randomized, double-blind
trials are required. The aim of this study will be to assess
the efficacy and safety of acupuncture treatments in
SAH patients for preventing delayed cerebral vasospasm
through a randomized controlled trial.
Methods
This study will be a single-center, randomized, placebo-
controlled, parallel group, patient-assessor-blinded clin-
ical trial. The study will be conducted at Kyung Hee
University Hospital in Gangdong, Seoul, Korea.
Ethics
The trial will be carried out in accordance with the
Declaration of Helsinki and the Korean Good Clinical
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committee of the Kyung Hee University Hospital at
Gangdong (KHNMC-OH-IRB 2014-001-002). It has been
registered on www.clinicaltrials.gov (NCT02275949) and
will be reported in compliance with the CONSORT state-
ment (www.consort-statement.org).
Participants
Subject enrollment, randomization, and blinding
A total of 80 participants will be recruited for this trial.
Patients with SAH admitted to our hospital are potential
candidates for the study. Eligible participants will be
randomized to the study group or the control group after
written informed consent is obtained. Concealed allocation
will be achieved by randomization and allocation by an
assigned researcher without patient contact. Randomization
will be done using a computer-generated allocation list by
an assigned researcher not involved in the intervention or
assessment. Stratified block randomization will be carried
out according to sex and the Hunt and Hess Scale (HHS)
[25]. The physician involved in the intervention will receive
a random number by phone after the informed consentFigure 1 The flow chart. HHS, the Hunt and Hess Scale; FG, the Fisher grad
neurological deficit.form has been signed and the HHS has been evaluated. A
flow chart of the study is presented in Figure 1.
The participants and the outcome assessors will be
blinded to the type of intervention used. The practi-
tioner will not provide any clues about the allocation
information to the participants during the study. Blind-
ing will be maintained until the study is completed.Inclusion criteria
Participants conforming to all the following conditions
will be included: (1) SAH verified by computed tomog-
raphy (CT) and cerebral angiography; (2) aneurysm
treated by endovascular coiling or surgical clipping;
(3) age > 18 years; (4) HHS 1 to 4; (5) acupuncture treat-
ment can start within 96 h after SAH; and (6) participation
is voluntary and the informed consent form is signed.Exclusion criteria
Participants with any of the following conditions will
be excluded: 1) traumatic or infectious SAH; 2) HHS 5;
3) transcranial Doppler (TCD) cannot be performed;e; mRS, modified Rankin Scale; NO, nitric oxide; DIND, delayed ischemic
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pacemaker; or 6) have experience of electro-acupuncture.
Intervention
Intervention will start within 96 h of SAH, after rup-
tured aneurysms have been secured by endovascular
coiling or surgical clipping. Interventions will be applied
once a day, 6 days a week for 2 weeks (a total of 12
sessions) in addition to standard treatments such as
prophylactic hypertensive, hypervolemic, and hemodilu-
tion (triple-H) therapy and nimodipine. Sterile dispos-
able stainless steel acupuncture needles (length, 4 cm;
diameter, 0.25 mm) will be used. All interventions will
be performed by one Korean Medicine doctor with over
3 years of working experience who completed a college
education of 6 years. This doctor will be trained in the
study protocol before the start of the trial.
Study group
Acupuncture, electroacupuncture, and intradermal acu-
puncture will be performed at every session. Acupunc-
ture needles (Dong Bang Acupuncture Inc., Chungnam,
Korea) will be inserted bilaterally at the acupuncture
points Zusanli (ST36), Neiguan (PC6), Gongsun (SP4),
and Xiangu (ST43). After insertion to a depth of
approximately 1.5 cm, the needles will be manually stim-
ulated until de qi (a subjective experience in which
patients feel a radiating sensation considered indicative
of effective needling) is achieved.
An electric stimulator (ES-160, ITO Co., Japan) will be
connected to the handle of each needle in the ST36 and
PC6 positions and a current of 5 Hz applied. The
current intensity will be increased until light muscle
contraction is evident and reaches approximately 70% of
bearable intensity. The needles will be left in place for
20 min and then removed. The practitioner will be able
to regulate the intensity in response to requests from
the subjects.
After the needles are removed, intradermal acupunc-
ture needles with tape (DB130A, 0.25 mm × 1.5 mm,
Dong Bang Acupuncture Inc., Chungnam, Korea) will be
inserted bilaterally in the ST36, PC6, SP4, and ST43
positions and maintained until the next session.
Control group
Mock transcutaneous electrical nerve stimulation and
sham intradermal acupuncture will be carried out by the
same Korean Medicine doctor. After an electrical insula-
tor (Medi trace 200 foam electrodes, Ludlow Technical
Products Canada, Ltd., Ontario, Canada) is attached
bilaterally in the ST36 and PC6 positions, the same elec-
tric stimulator will be connected to the same points as
used in the study group, but without application of
current. The subjects in the control group will see thesame lights and hear the same sounds coming from
the machine as the study group. After 20 min, the elec-
trical insulator will be removed and sham intradermal
acupuncture will be performed at the same points. 3 M
micropore medical tape (1 cm × 1 cm) will be placed
on the skin. After intradermal acupuncture needles are
placed over the tape but not penetrating the skin,
micropore medical tape of the same size will be placed
over the needles. This will remain in place until the
next session.
Assessment
The evaluation of each assessment scale will be per-
formed by an investigator blinded to the assigned group.
A baseline assessment will include Fisher grade (FG),
HHS, modified Rankin Scale (mRS), NO and endothelin-1
in plasma [26]. The occurrence of delayed ischemic neuro-
logical deficit (DIND), TCD vasospasm, angiographic
vasospasm and a vasospasm-related cerebral infarction
will be monitored during the study period. DIND is
defined as an unaccountable new focal neurological deficit
lasting >2 hours with either angiography or transcranial
Doppler findings [27]. TCD (Transcranial Doppler Sys,
2-channel, DWL, Germany) monitoring will be done by
a skilled researcher at a certain time every other day
[8]. CT angiography or conventional cerebral angiog-
raphy will be performed when an abnormal increase in
blood flow velocity is shown or any neurological
changes occur [4,10]. If necessary, we will check
whether vasospasm-related infarction has occurred
using CT or magnetic resonance imaging (MRI) [8].
Modified Rankin scale will be measured after 2 weeks,
and the follow-up assessment will be conducted 2
weeks after the primary endpoint in order to evaluate
mortality and mRS.
Combined treatment
All participants will receive conventional therapy in the
same way. This is defined as general neurosurgical man-
agement carried out in SAH patients to stabilize the vital
signs, control pain, and prevent vasospasm through fluid
or medication therapy. Any use of medication will be
recorded on the case report forms every day.
Dropout criteria
Participants conforming to any of following conditions
will be removed from the study: (1) more than three ses-
sions (out of a total of 12) are not performed; (2) with-
drawal of patient consent; (3) severe adverse events
making the trial unsustainable; (4) worsening condi-
tion making it difficult to participate in the trial; or
(5) impractical to continue with the trial, as judged
by the principal investigator.
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Primary outcome measurement
The occurrence of DIND will be compared between the
study group and the control group. DIND is defined as
an unaccountable new focal neurological deficit lasting
≥2 h. Any occurrence of DIND will be recorded by the
physician and verified by the investigator every day.
Secondary outcome measurements
Secondary outcome measures are as follow:
1. Incidence of angiographic vasospasm
Angiographic vasospasm is defined as focal or
generalized reduction of cerebral arterial caliber
on conventional cerebral angiogram or CT angiography
confirmed by a neuroradiologist and a neurosurgeon.
2. Incidence of TCD vasospasm
TCD vasospasm is defined as a peak systolic middle
cerebral artery velocity (PCAMCA) of >200 cm/s and
a Lindegaard ratio of >3 (Lindegaard ratio = mean
velocity in the MCA/mean velocity in the ipsilateral
extracranial internal carotid artery) [28-30].
3. Incidence of vasospasm-related infarct on CT or MRI
A vasospasm-related infarct is defined as a cerebral
infarction in the region of angiographic vasospasm
or TCD vasospasm as shown on CT or MRI.
4. Changes in plasma NO and endothelin-1
A blood sample (3 mL) will be taken from the brachial
vein, centrifuged at 3,000 rpm for 15 min, and kept in
a freezer at -70°C before analysis. The concentration
of NO will be analyzed using a Total Nitric Oxide and
Nitrate/Nitrate Parameter Assay Kit (R&D Systems,
Inc., USA) and the level of endothelin-1 will be
measured using an Endothelin-1 Quantikine ELISA
Kit (R&D Systems, Inc., USA). All samples will be
discarded after analysis (www.rndsystems.com).
5. Mortality at the end of treatment and 14 days after
treatment (or at discharge)
6. Modified Rankin Scale (mRS) score
Functional status is assessed with mRS score at the
end of treatment and 14 days after treatment (or at
discharge).
Safety evaluation
Any adverse events or abnormalities will be recorded
in the case report forms irrespective of the interven-
tion used. Severity will be evaluated as mild, moderate,
or severe, and the relation of any events to the inter-
vention will be evaluated as not related, possibly
related, or related.
If any serious adverse events occur, the intervention
will be stopped immediately and appropriate action will
be taken. This will be reported promptly to the institu-
tional review board, according to the protocol.Sample size estimation
DIND, the primary outcome of the trial, was used to cal-
culate the sample size. According to our pilot trial car-
ried out in 2012, the incidence rate of DIND was 10% in
the study group and 38.9% in the control group [24].
The difference in the expected incidence rate of DIND
between the two groups (Pc - Pt) is therefore 28.9%. To
detect this difference with a two-sided 5% significance
level and a power of 95%, 39 participants per interven-
tion arm have to be randomized, allowing for a 20%
dropout rate [31].
n ¼ zα=2 þ zβ
 2
pcqc þ ptqtð Þ
pc−ptð Þ2
Statistical analyses
According to the principle of intention-to-treat, all ran-
domized participants will be analyzed using SPSS version
18.0 (SPSS Inc., Chicago, IL, USA) software. All data will
be represented as mean ± standard deviation (SD) or
number (%). For comparisons of two groups, an inde-
pendent samples t-test or Mann- Whitney U test will be
used for continuous outcomes, and a χ2-test or Fisher’s
exact test will be used for noncontinuous outcomes. To
control for possible confounding factors (for example, age,
Hunt and Hess Scale, modified Rankin Scale, etcetera),
multiple regression analysis will be performed for the
comparison of two groups. Confidence limits of 95% will
be calculated and P values of < 0.05 will be considered
statistically significant.
Discussion
In this randomized controlled trial, we aim to observe
the effect of acupuncture treatment on the prevention of
vasospasm after SAH. In addition to the occurrence of
DIND and vasospasm, plasma levels of NO and
endothelin-1 will be evaluated to identify the mechanism
of action of the treatments used. Stratified block
randomization will be used according to sex and severity
(HHS). For the placebo control, we will use an electric
stimulator without electrical flow and sham intradermal
acupuncture designed not to penetrate the skin. With
use of the same electrical stimulator and intradermal
acupuncture method as the treatment group, better
blinding of the control group is expected. Participants
will be treated alone in a treatment room in order to
avoid any communication with other participants.
In summary, the effect of acupuncture treatment on
the prevention of vasospasm after SAH will be assessed
in this trial. The placebo effect should be excluded and
the trial design should allow for evaluation of the effi-
cacy and safety of acupuncture for SAH patients.
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Recruitment started in September 2014 and will be com-
pleted by the end of May 2016.
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